newsfilter
← Latest News
GlobeNewswire·

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

Study Highlights Dagger® Technology Showing that an Optimized CD70 CAR has the Potential to Protect Against Immune Rejection, Enabling Robust Expansion and Persistence of Allogeneic CAR T Cells in Pre-Clinical